Results 111 to 120 of about 128,688 (309)

Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine

OncoImmunology
The α2-adrenergic receptor agonist dexmedetomidine (DEX) exerts context-dependent antitumor effects, with its efficacy influenced by dose, immune cell involvement and combination with immune checkpoint inhibitors.
Lucillia Bezu, Oliver Kepp, Guido Kroemer   +2 more
doaj   +1 more source

The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. [PDF]

, 1996
Thomas W. Gettys, P J Harkness, Paul Watson   +2 more
openalex   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Distribution and cellular localization of imidazoleacetic acid-ribotide, an endogenous ligand at imidazol(in)e and adrenergic receptors, in rat brain

, 2007
Victor L. Friedrich, Giorgio P. Martinelli, George D. Prell, Gay R. Holstein   +3 more
openalex   +1 more source

A label-free optical biosensor with microfluidics identifies an intracellular signalling wave mediated through the β2-adrenergic receptor [PDF]

, 2013
Ann M. Ferrie, Chaoming Wang, Huayun Deng, Fang Ye   +3 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Heat Shock–Related Protein 20 Peptide Decreases Human Airway Constriction Downstream of β₂-Adrenergic Receptor

, 2016
Alex Banathy, Joyce Cheung‐Flynn, Kasia Goleniewska, Kelly L. Boyd, Dawn C. Newcomb, R. Stokes Peebles, Padmini Komalavilas   +6 more
openalex   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

α₂ Adrenoceptor Agonists as Potential Analgesic Agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene as a High-Affinity Ligand for the α_2D Adrenergic Receptor

, 2000
Tina Morgan Ross, Michele C. Jetter, Mark E. McDonnell, Robert E. Boyd, Charlene D. Connelly, Rebecca P. Martinez, Martin Lewis, Ellen E. Codd, Robert B. Raffa, Allen B. Reitz   +9 more
openalex   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source